Repligen Corporation $RGEN Shares Sold by Amundi

Amundi lowered its stake in Repligen Corporation (NASDAQ:RGEN) by 0.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 85,297 shares of the biotechnology company’s stock after selling 566 shares during the period. Amundi owned 0.15% of Repligen worth $10,381,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raiffeisen Bank International AG purchased a new stake in Repligen during the 4th quarter valued at about $29,000. Twin Tree Management LP acquired a new stake in shares of Repligen during the first quarter worth about $29,000. Signaturefd LLC boosted its position in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 128 shares during the last quarter. Center for Financial Planning Inc. raised its position in Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock worth $47,000 after buying an additional 193 shares during the last quarter. Finally, UMB Bank n.a. raised its position in Repligen by 99.4% during the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $85,000 after buying an additional 332 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ:RGEN opened at $118.69 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The company has a fifty day moving average of $121.30 and a two-hundred day moving average of $128.72. The stock has a market capitalization of $6.68 billion, a PE ratio of -474.74, a P/E/G ratio of 2.22 and a beta of 1.07. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same quarter last year, the business earned $0.40 EPS. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of research reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Stephens raised Repligen to an “overweight” rating and set a $160.00 price objective for the company in a report on Tuesday, July 22nd. Barclays began coverage on Repligen in a report on Tuesday, June 24th. They set an “overweight” rating and a $150.00 target price on the stock. Finally, Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a report on Sunday, June 29th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and an average target price of $169.55.

Insider Buying and Selling

In other news, Director Martin D. Madaus bought 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director directly owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.